KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Gross Margin (2017 - 2026)

Aquestive Therapeutics has reported Gross Margin over the past 9 years, most recently at 153.65% for Q4 2025.

  • For Q4 2025, Gross Margin rose 9173.0% year-over-year to 153.65%; the TTM value through Dec 2025 reached 87.12%, up 1817.0%, while the annual FY2025 figure was 87.12%, 1817.0% up from the prior year.
  • Gross Margin for Q4 2025 was 153.65% at Aquestive Therapeutics, up from 64.82% in the prior quarter.
  • Over five years, Gross Margin peaked at 153.65% in Q4 2025 and troughed at 123.3% in Q2 2021.
  • A 5-year average of 58.08% and a median of 63.34% in 2023 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 48450bps in 2021 and later plummeted -3641bps in 2024.
  • Year by year, Gross Margin stood at 69.62% in 2021, then dropped by -28bps to 50.34% in 2022, then grew by 16bps to 58.49% in 2023, then increased by 6bps to 61.91% in 2024, then soared by 148bps to 153.65% in 2025.
  • Business Quant data shows Gross Margin for AQST at 153.65% in Q4 2025, 64.82% in Q3 2025, and 54.4% in Q2 2025.